{"product_id":"nbix-ansoff-analysis","title":"(NBIX) Neurocrine Biosciences, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExplore the Complete Growth Strategy Behind the Preview\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Neurocrine Biosciences, Inc. Ansoff Matrix Analysis helps you assess the company’s growth options across market penetration, market development, product development, and diversification in a clear, structured framework; the page already includes a real preview\/sample so you can evaluate style and substance before buying. Purchase the full version to receive the complete, ready-to-use analysis for strategy, investment, or planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eINGREZZA in tardive dyskinesia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eINGREZZA is Neurocrine Biosciences, Inc.'s main commercial asset for tardive dyskinesia, so market penetration means getting more use from the same specialist base. In a U.S. pool of about 600,000 people with tardive dyskinesia, the real lever is more starts, better persistence, and stronger refills. That supports higher script volume without needing a new indication.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eONGENTYS in Parkinson’s add-on therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eONGENTYS is an add-on to levodopa\/DOPA decarboxylase inhibitors, so market penetration depends on neurologists moving it into the current Parkinson’s pathway. Neurocrine Biosciences, Inc. is using it to deepen its movement-disorder franchise rather than open a new market. That makes adoption, not category creation, the main growth lever.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eORILISSA in endometriosis pain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eORILISSA is a same-market share play in moderate to severe endometriosis pain, aimed at deepening use within the same women’s health specialist base. Endometriosis affects about 1 in 10 women of reproductive age, giving Neurocrine Biosciences, Inc. a large, established patient pool to defend and grow from an approved brand already on market since 2018.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eORIAHNN in uterine fibroid bleeding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eORIAHNN is a direct existing-product, existing-market push for Neurocrine Biosciences, Inc.: it targets pre-menopausal women with heavy menstrual bleeding from uterine fibroids, a condition that affects up to 70% of women by age 50. In this market, penetration means winning more prescriptions from clinicians who already treat fibroid bleeding, not creating a new category.\u003c\/p\u003e\n\u003cp\u003eThat matters because 1 in 3 women with fibroids report heavy bleeding, and ORIAHNN offers an oral, non-surgical option that can fit earlier in treatment paths. The commercial goal is simple: raise awareness, improve trial rates, and convert gynecology visits into repeat use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExisting product\u003c\/li\u003e\n\u003cli\u003eExisting market\u003c\/li\u003e\n\u003cli\u003eClinician adoption drive\u003c\/li\u003e\n\u003cli\u003eOral, non-surgical option\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAbbVie women’s health commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNeurocrine’s women’s health penetration is tied to its collaboration with AbbVie Inc., which commercializes 2 key assets, ORILISSA and ORIAHNN. This expands reach in a current market where ORILISSA launched in 2018 and ORIAHNN in 2020, helping Neurocrine deepen share without building a full standalone sales force.\u003c\/p\u003e\n\u003cp\u003eAbbVie’s larger women’s health sales network gives these products wider physician access and payer coverage, which is the clearest market-penetration lever in the Ansoff matrix. The partnership is practical, asset-light, and aimed at growing volume in an existing category.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2 marketed women’s health assets\u003c\/li\u003e\n\u003cli\u003eORILISSA: 2018 launch\u003c\/li\u003e\n\u003cli\u003eORIAHNN: 2020 launch\u003c\/li\u003e\n\u003cli\u003eUses AbbVie’s commercial scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeurocrine’s Growth Play: More Volume From Existing Brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNeurocrine Biosciences, Inc.’s market penetration play is about pushing more volume from existing brands in current specialist channels: INGREZZA in tardive dyskinesia, ONGENTYS in Parkinson’s disease, and ORILISSA\/ORIAHNN in women’s health. The key levers are higher starts, better refill rates, and broader physician adoption in large diagnosed pools.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eMarket\u003c\/th\u003e\n\u003cth\u003ePenetration lever\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eINGREZZA\u003c\/td\u003e\n\u003ctd\u003e~600,000 TD patients\u003c\/td\u003e\n\u003ctd\u003eStarts and persistence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eORILISSA\u003c\/td\u003e\n\u003ctd\u003eEndometriosis\u003c\/td\u003e\n\u003ctd\u003eShare gain\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eORIAHNN\u003c\/td\u003e\n\u003ctd\u003eFibroid bleeding\u003c\/td\u003e\n\u003ctd\u003ePhysician adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Ansoff Matrix view of Neurocrine Biosciences, Inc.’s growth strategy across existing and new products and markets\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Neurocrine Biosciences Ansoff Matrix snapshot to quickly pinpoint growth options and reduce strategy uncertainty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCites primary, regulatory, and industry sources to fast-verify Neurocrine Biosciences growth paths in Ansoff Matrix analyses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eINGREZZA across broader specialty channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eINGREZZA can expand from early adopters into broader neurology and psychiatry referral channels, so Neurocrine Biosciences, Inc. widens the buyer base without changing the drug. In 2024, INGREZZA delivered about $1.9 billion in net product sales, showing strong demand to scale into more prescribing settings. That makes this a classic market development move: same brand, more clinics, more patients, more scripts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eONGENTYS in movement-disorder centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eONGENTYS is a levodopa add-on for Parkinson’s disease, so market development means pushing the same product into more movement-disorder centers and specialist clinics. Parkinson’s affects nearly 1 million people in the U.S., and ONGENTYS is dosed once daily at 50 mg or 25 mg with levodopa, which fits routine specialist care. Neurocrine expands reach without changing the indication, lifting access in centers that manage OFF episodes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eORILISSA through women’s health specialists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eORILISSA can grow by reaching more gynecology and women’s health prescribers, since this is a new channel expansion, not a new product launch. Neurocrine Biosciences, Inc. is still selling the same FDA-approved therapy for endometriosis pain, so wider prescriber access can lift use without new development risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eORIAHNN in broader fibroid care pathways\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eORIAHNN treats heavy menstrual bleeding linked to uterine fibroids in premenopausal women, so market development means moving it beyond narrow specialist use into broader fibroid care pathways. Uterine fibroids affect up to 77% of women by age 50, and only a share are diagnosed, so the same product can reach more women through OB\/GYN, primary care, and anemia workups.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame therapy, wider care access\u003c\/li\u003e\n\u003cli\u003eTargets premenopausal fibroid pathways\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner-led reach beyond direct promotion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNeurocrine Biosciences, Inc. can widen reach in specialist women’s health by using AbbVie’s sales force and payer access instead of relying only on direct promotion. That matters for niche brands like Orilissa and Oriahnn, where specialist prescribers and access hurdles shape uptake. Partner-led selling can lift market development faster and at lower fixed cost.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAbbVie broadens field coverage.\u003c\/li\u003e\n\u003cli\u003eSpecialist access improves launch speed.\u003c\/li\u003e\n\u003cli\u003eDirect spend stays focused.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeurocrine Grows by Expanding Approved Brands Into New Care Settings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMarket development for Neurocrine Biosciences, Inc. means using the same approved brands in more care settings, not changing the drugs. INGREZZA reached about $1.9 billion in 2024 net product sales, while ORILISSA, ORIAHNN, and ONGENTYS can gain by expanding into more neurology, OB\/GYN, and movement-disorder channels.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003eMarket development lever\u003c\/th\u003e\n\u003cth\u003eLatest cited data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eINGREZZA\u003c\/td\u003e\n\u003ctd\u003eBroader neuropsychiatry access\u003c\/td\u003e\n\u003ctd\u003e2024 sales: about $1.9B\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eNeurocrine Biosciences, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full Ansoff Matrix report you'll get, covering Neurocrine Biosciences' product-market strategies and recommended growth pathways.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNBI-921352 epilepsy program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNBI-921352 is a new product in clinical development for 2 groups: pediatric patients and adults with focal epilepsy, so it fits Ansoff Matrix market development inside Neurocrine Biosciences, Inc.’s core neuroscience area. It supports the company’s strategy of turning pipeline assets into approved therapies, while targeting an existing epilepsy market with a differentiated next wave asset. Neurocrine Biosciences, Inc. reported $1.9 billion in 2024 revenue, showing the scale behind this pipeline push.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNBI-827104 rare pediatric epilepsy and essential tremor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNBI-827104 is a direct product-development move: Neurocrine Biosciences, Inc. is moving it from discovery into clinical testing for rare pediatric epilepsy and essential tremor. That broadens the pipeline beyond its core neuroscience base, where 2025 net product sales were still led by INGREZZA at more than $2 billion. Rare epilepsy also matters because severe childhood epilepsy affects about 1 in 200 children.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNBI-1065845 major depressive disorder\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNBI-1065845 is Neurocrine Biosciences, Inc.'s psychiatry candidate for major depressive disorder, so this is product development: a new therapy aimed at an established market. Neurocrine Biosciences, Inc. reported $2.4 billion in 2025 revenue, and adding NBI-1065845 broadens its CNS pipeline beyond approved products like INGREZZA. If successful, it could open a new growth lane in depression, a large and still underserved market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNBI-1065846 anhedonia in MDD\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNBI-1065846 is a symptom-targeted MDD asset aimed at anhedonia, the loss of pleasure that drives poor function and often persists even when mood lifts. That makes it a differentiated new-product bet in Neurocrine Biosciences, Inc.’s depression franchise, with MDD affecting about 280 million people worldwide and anhedonia reported in roughly 40% to 70% of MDD cases.\u003c\/p\u003e\n\u003cp\u003eIn Ansoff terms, this is product development: a new therapy for an existing psychiatric market, but narrowed to a defined symptom segment. The strategy can improve clinical fit and pricing power if it proves better than broad antidepressants, where only about one-third of patients reach remission after first treatment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets a high-burden MDD symptom\u003c\/li\u003e\n\u003cli\u003eRefines the pipeline to anhedonia\u003c\/li\u003e\n\u003cli\u003eFits product development, not market expansion\u003c\/li\u003e\n\u003cli\u003eUses a differentiated, niche depression concept\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNBI-118568 schizophrenia program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNBI-118568 is Neurocrine Biosciences, Inc.’s schizophrenia candidate, so this is a clear product-development move that pushes its CNS pipeline beyond current commercial brands. Schizophrenia affects about 24 million people worldwide, and the U.S. schizophrenia drugs market is still a multibillion-dollar space, so even a small share can matter.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpands psychiatric reach\u003c\/li\u003e\n\u003cli\u003eTargets a large CNS market\u003c\/li\u003e\n\u003cli\u003eAdds pipeline depth beyond brands\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeurocrine’s Pipeline Push Fuels the Next Phase of CNS Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNeurocrine Biosciences, Inc.’s product development strategy centers on new CNS and psychiatry assets, including NBI-921352, NBI-827104, NBI-1065845, NBI-1065846, and NBI-118568. These programs extend its pipeline into epilepsy, depression, anhedonia, and schizophrenia, while building on 2025 revenue of $2.4 billion and INGREZZA sales above $2 billion. This is classic product development: new products for existing disease markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eAnsoff move\u003c\/th\u003e\n\u003cth\u003e2025 data point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNBI-1065845\u003c\/td\u003e\n\u003ctd\u003eProduct development\u003c\/td\u003e\n\u003ctd\u003eMDD target\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNBI-118568\u003c\/td\u003e\n\u003ctd\u003eProduct development\u003c\/td\u003e\n\u003ctd\u003eSchizophrenia target\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeurocrine Biosciences, Inc.\u003c\/td\u003e\n\u003ctd\u003ePipeline-backed growth\u003c\/td\u003e\n\u003ctd\u003e$2.4B revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e8 strategic partners network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeurocrine Biosciences has 8 strategic partners, including Heptares, Takeda, Idorsia, Xenon, Voyager, BIAL, Mitsubishi Tanabe, and AbbVie. This licensing and collaboration web spreads R\u0026amp;D risk across multiple external innovation sources and business models. It also reduces reliance on a single program, which can protect pipeline value if one partner or asset underperforms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeptares and Takeda collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHeptares Therapeutics and Takeda Pharmaceutical give Neurocrine Biosciences two external science channels, so growth is not tied only to its internal pipeline. That is diversification through partnered innovation, with access to outside assets, targets, and development risk sharing. It also broadens Neurocrine’s shot at new CNS programs without building every asset in-house.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIdorsia and Xenon partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIdorsia and Xenon give Neurocrine Biosciences, Inc. more outside neuroscience links, which adds option value in new programs and mechanisms. That matters because one approved brand, INGREZZA, drove about $2.5 billion in 2024 sales, so more shots on goal can lower single-product risk. It also spreads discovery exposure beyond one path and one deal.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVoyager gene-therapy linkage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVoyager Therapeutics gives Neurocrine Biosciences a gene-therapy route outside its core small-molecule play, so the tie-up is true diversification, not just brand extension. It widens R\u0026amp;D exposure to CNS delivery and long-duration treatment models, which can change the pipeline mix and risk profile.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMoves beyond internal brand expansion\u003c\/li\u003e\n\u003cli\u003eAdds gene-therapy science and delivery know-how\u003c\/li\u003e\n\u003cli\u003eBroadens product and partner exposure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBIAL and Mitsubishi Tanabe regional reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBIAL Portela \u0026amp; Ca and Mitsubishi Tanabe Pharma give Neurocrine Biosciences, Inc. a 2-partner footprint across Europe and Japan, so diversification is not just by product but by geography too. That wider reach can lower single-market risk and support future cross-border development and commercialization.\u003c\/p\u003e\n\u003cp\u003eWith 2 established partners, Neurocrine Biosciences, Inc. can share development cost and regulatory load across markets, which matters when one program faces delays or a weaker launch in one region. The setup also spreads commercial risk across 2 separate demand bases.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2 partners, wider geography\u003c\/li\u003e\n\u003cli\u003eEurope and Japan access\u003c\/li\u003e\n\u003cli\u003eShared product and launch risk\u003c\/li\u003e\n\u003cli\u003eSupports cross-border expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeurocrine Spreads Risk with 8 Strategic Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNeurocrine Biosciences uses diversification through 8 strategic partners, not just internal R\u0026amp;D. That spreads discovery risk across CNS, gene therapy, and regional deals.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartners\u003c\/td\u003e\n\u003ctd\u003e8\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eINGREZZA sales\u003c\/td\u003e\n\u003ctd\u003e$2.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeographies\u003c\/td\u003e\n\u003ctd\u003eEurope, Japan\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234788942089,"sku":"nbix-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/nbix-ansoff-matrix.webp?v=1785725962","url":"https:\/\/dcfanalyst.com\/products\/nbix-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}